Medical Editor: John P. Cunha, DO, FACOEP
Adrucil (fluorouracil injection) is a nucleoside metabolic inhibitor indicated for the treatment of patients with adenocarcinoma of the colon and rectum, adenocarcinoma of the breast, gastric adenocarcinoma, or pancreatic adenocarcinoma. The brand name Adrucil has been discontinued. It may be available in generic form. Common side effects of Adrucil (fluorouracil) include:
- low red and white blood cells and platelets,
- gastrointestinal ulcers,
- severe allergic reaction (anaphylaxis),
- other allergic reactions,
- involuntary eye movement,
- dry or cracking skin,
- skin sensitivity to sunlight (redness or dark spots on skin),
- tear duct obstruction,
- changes in vision,
- eye sensitivity to light,
- inflammation of veins caused by blood clots,
- nosebleed, and
- nail changes (including loss of nails).
The recommended dose and regimen for Adrucil (fluorouracil) depends on the condition being treated. Adrucil (fluorouracil) may interact with anticoagulants. Tell your doctor all medications and supplements you use. Adrucil (fluorouracil) is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Adrucil (fluorouracil) and for up to 3 months after stopping. Adrucil (fluorouracil) may damage spermatozoa. Males with female partners of reproductive potential are advised to use effective contraception during and for 3 months after stopping. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended while using Adrucil (fluorouracil).
Our Adrucil (fluorouracil injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following adverse reactions are discussed in more detail in other sections of the labeling:
- Increased risk of serious or fatal adverse reactions in patients with low or absent dipyrimidine dehydrogenase activity [see WARNINGS AND PRECAUTIONS]
- Cardiotoxicity [see WARNINGS AND PRECAUTIONS]
- Hyperammonemic encephalopathy [see WARNINGS AND PRECAUTIONS]
- Neurologic toxicity [see WARNINGS AND PRECAUTIONS]
- Diarrhea [see WARNINGS AND PRECAUTIONS]
- Palmar-plantar erythrodysesthesia (hand-foot syndrome) [see WARNINGS AND PRECAUTIONS]
- Myelosuppression [see WARNINGS AND PRECAUTIONS]
- Mucositis [see WARNINGS AND PRECAUTIONS]
- Increased risk of elevated INR when administrated with warfarin [see WARNINGS AND PRECAUTIONS]
The following adverse reactions have been identified during postapproval use of fluorouracil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hematologic: pancytopenia [see WARNINGS AND PRECAUTIONS]
Gastrointestinal: gastrointestinal ulceration, nausea, vomiting
Allergic Reactions: anaphylaxis and generalized allergic reactions
Neurologic: nystagmus, headache
Dermatologic: dry skin; fissuring; photosensitivity, as manifested by erythema or increased pigmentation of the skin; vein pigmentation
Ophthalmic: lacrimal duct stenosis, visual changes, lacrimation, photophobia
Miscellaneous: thrombophlebitis, epistaxis, nail changes (including loss of nails)
Read the entire FDA prescribing information for Adrucil (Fluorouracil Injection)